FDA Inspection 1166633 — Roshanak Monzavi, M.D.
The FDA completed an inspection of Roshanak Monzavi, M.D. on Apr 1, 2022 in Los Angeles, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 1, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Los Angeles, CA (United States)
Additional Details
Clinical Investigator (CI)